MRK•benzinga•
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summary
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 23, 2025 by benzinga